In this Issue:
Efficacy of pembrolizumab
Pembrolizumab for ipilimumab refractory melanoma
Long-term survival of ipilimumab-naïve patients treated with nivolumab
BRAF mutation status and nivolumab and ipilimumab therapy outcome
Vemurafenib treatment in metastatic melanoma patients with BRAF V600 mutation-positive
MAPK reactivation in early resistance to dabrafenib/trametinib therapy of BRAF mutant metastatic melanoma
Genomic characterisation of cutaneous melanoma
BKM120 antitumor activity in melanoma brain metastases in vitro and in vivo
PDL1 expression and tumour infiltrating lymphocytes and subsets of MAPK inhibitor-treated melanoma patients
Characteristics of TP53 mutations in patients with melanoma
Please login below to download this issue (PDF)